Patients who took a GLP-1 receptor agonist before surgery did not lose more weight at one year, JAMA Surgery reports. The full study has the details.
Recap by typeshit. Post by JAMA Surgery on X.
6:25
Dr Almerie compares Lilly's experimental retatrutide with Mounjaro and talks through the case for switching versus holding off until it's approved.
He points to GLP-1 receptors in the hypothalamus, saying the medication boosts fullness signals and slows the stomach, which changes how hunger feels.
10:08
Weight loss doctor Bazgha Khalid goes through what the published trials actually show for Zepbound against Lilly's newer retatrutide.
A clinical piece for foot and limb care providers on how GLP-1 drugs relate to the lower extremity. Only the title is available.
The Irish Independent talked to four people about the weight loss and health benefits they credit to GLP-1s, ahead of Ozempic's tenth year on the market in Ireland.
Obesity doctor Spencer Nadolsky posts a short clip naming three common errors he sees among people taking GLP-1 medications.
Loading…